Anna Di Benedetto

List of Publications by Year
in descending order

35 papers	1,074 citations	516710 16 h-index	395702 33 g-index
35 all docs	35 docs citations	35 times ranked	2110 citing authors

#	Article	IF	Citations
1	A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Research and Treatment, 2012, 133, 949-958.	2.5	119
2	HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. Clinical Cancer Research, 2011, 17, 2055-2064.	7.0	92
3	A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Research, 2008, 10, R74.	5.0	89
4	High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. Journal of Clinical Investigation, 2007, 117, 693-702.	8.2	88
5	miRâ€10b*, a master inhibitor of the cell cycle, is downâ€regulated in human breast tumours. EMBO Molecular Medicine, 2012, 4, 1214-1229.	6.9	85
6	The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2â€“Positive/Hormonal Receptorâ€“Negative Tumors. Clinical Cancer Research, 2006, 12, 1470-1478.	7.0	73
7	ATM kinase sustains HER2 tumorigenicity in breast cancer. Nature Communications, 2015, 6, 6886.	12.8	50
8	Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Scientific Reports, 2017, 7, 45293.	3.3	50
9	Overexpression of activated phospholipase CÎ³1 is a risk factor for distant metastases in T1â€T2, N0 breast cancer patients undergoing adjuvant chemotherapy. International Journal of Cancer, 2013, 132, 1022-1031.	5.1	41
10	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget, 2014, 5, 9619-9625.	1.8	35
11	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget, 2016, 7, 43188-43198.	1.8	35
12	Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. Journal of Experimental and Clinical Cancer Research, 2018, 37, 95.	8.6	25
13	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. Breast Cancer Research and Treatment, 2014, 148, 73-80.	2.5	24
14	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. Journal of Experimental and Clinical Cancer Research, 2016, 35, 62.	8.6	24
15	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. Cancer Biology and Therapy, 2017, 18, 339-346.	3.4	22
16	Cdx2 Polymorphism Affects the Activities of Vitamin D Receptor in Human Breast Cancer Cell Lines and Human Breast Carcinomas. PLoS ONE, 2015, 10, e0124894.	2.5	21
17	Androgen receptor and antiandrogen therapy in male breast cancer. Cancer Letters, 2015, 368, 20-25.	7.2	17
18	hMENA isoforms impact NSCLC patient outcome through fibronectin/Î²1 integrin axis. Oncogene, 2018, 37, 5605-5617.	5.9	17

#	Article	IF	Citations
19	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 699-706.	1.8	16
20	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. Clinical Cancer Research, 2017, 23, 2575-2583.	7.0	16
21	Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. Journal of Translational Medicine, 2018, 16, 129.	4.4	16
22	Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas. BMC Cancer, 2010, 10, 151.	2.6	14
23	Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer. Journal of Experimental and Clinical Cancer Research, 2010, 29, 125.	8.6	14
24	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. Scientific Reports, 2017, 7, 8078.	3.3	14
25	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget, 2015, 6, 42773-42780.	1.8	14
26	Neoadjuvant Sequential Docetaxel Followed by Highâ€Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. Journal of Cellular Physiology, 2016, 231, 2541-2547.	4.1	12
27	Body mass index modifies the relationship between Î³-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. BMC Cancer, 2017, 17, 101.	2.6	12
28	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. Journal of Cellular Physiology, 2017, 232, 2246-2252.	4.1	9
29	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. Scientific Reports, 2016, 6, 35121.	3.3	6
30	Bio-pathologic Characteristics Related to Chromosome 11 Aneusomy and Cyclin D1 Gene Status in Surgically Resected Stage I and II Breast Cancer: Identification of an Adverse Prognostic Profile. American Journal of Surgical Pathology, 2007, 31, 247-254.	3.7	5
31	Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile?. Journal of Clinical Oncology, 2011, 29, 2834-2835.	1.6	5
32	Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma. Journal of Thoracic Disease, 2016, 8, 386-395.	1.4	4
33	Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. Journal of Experimental and Clinical Cancer Research, 2017, 36, 143.	8.6	4
34	p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study. Clinical Breast Cancer, 2020, 20, e761-e770.	2.4	4
35	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985319.	3.2	2